AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02925520
Drug: Omegaven
RxNorm normalized name: Omegaven
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy with Omegaven will be provided at a dose of 1 gm/kg/day infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Parenteral fat emulsion (Intralipid) will be administered only if necessary to administer adequate calories during Omegaven therapy. The same standards of care provided to all patients receiving parenteral nutrition solution will be followed.~Home Use of Omegaven:~The Omegaven dose for home use will be the same as that used while in the hospital: 1 gm/kg/day. As with the inpatient part of the protocol, this is a maximum dose and may be decreased at the discretion of the provider.
Trial: NCT06120491
Drug: Saruparib
RxNorm normalized name: Saruparib
DrugBank: Saruparib (DB18982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT06120491
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral
Trial: NCT06120491
Drug: Darolutamide
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral
Trial: NCT06120491
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT04793867
Drug: Xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (\~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, scout images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time \<10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose.
Trial: NCT05664113
Drug: Fecal microbiota transplant (FMT)
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMT Lower Delivery Microbiota Preparation, Dose: 250 mL of Microbiota Preparation Material and Route of administration: colonoscopy FMT Upper Delivery Microbiota Preparation, Dose: 60 mL of Microbiota Preparation Material and Route of administration: Naso-enteral tube
Trial: NCT06411249
Drug: Belimumab (GSK1550188)
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: GSK1550188 will be administered subcutaneously.
Trial: NCT06680882
Drug: prucapride
RxNorm normalized name: prucalopride
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: was administered prucapride as a monotherapy
Trial: NCT03937830
Drug: durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1,150 mg flat dose every 21 days, starting on day 1 of cycle 1
Trial: NCT03937830
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7.5 mg/kg dose every 21 days, starting on day 1 of cycle 2
Trial: NCT03937830
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300, 150 or 75 mg once on day 1 of cycle 1
Trial: NCT03814109
Drug: Levamlodipine 2.5/ 5 mg
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet, oral, once a day.
Trial: NCT06528483
Drug: Sacituzumab Govitecan + Zimberelimab
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab Govitecan 7.5 mg/kg IV for 3 cycles Zimberelimab 360 mg IV for 16 cycles~Patients will be treated with Sacituzumab Govitecan 1,8q21 plus + Zimberelimab q21 for 3 cycles then radiological imaging and TURB will be repeated and patients with Stability of disease or down staging will continue Zimberelimab until disease progression, or unacceptable toxicities or completion of treatment (16 cycles). Patients with progressive disease after 3 cycles of study intervention will be treated as per clinical practice.
Trial: NCT05777993
Drug: Mitapivat
RxNorm normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT05167487
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
Trial: NCT05167487
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
Trial: NCT05257993
Drug: Gemcitabine-nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * After IV administration of nab-paclitaxel 125 mg/m2 for 30 minutes~* IV administration of Gemcitabine 1000 mg/m2 for 30 minutes~* Administration on Days 1, 8, and 15 on a 28-day cycle
Trial: NCT06247787
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Receive IV and IT
Trial: NCT06247787
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive IV
Trial: NCT05446870
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
Trial: NCT05446870
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle
Trial: NCT05446870
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
Trial: NCT00293527
Drug: Interferon Alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05514717
Drug: XMT-2056
RxNorm normalized name: XMT-2056
DrugBank: XMT-2056 (DB18230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XMT-2056 will be administered through a vein in your arm or port catheter (intravenously)
Trial: NCT05015439
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The study intervention will be supplied as a softgel capsule containing cannabidiol.
Trial: NCT03816488
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (usual dose) administered 2 h before surgery
Trial: NCT05208762
Drug: PF-08046054
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given into the vein (IV; intravenously)
Trial: NCT05208762
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg once every 3 weeks given into the vein (IV; intravenously)
Trial: NCT05796167
Drug: Pimavanserin
RxNorm normalized name: Pimavanserin
DrugBank: Pimavanserin (DB05316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks
Trial: NCT05537948
Drug: Pitavastatin
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of Pitavastatin: Pitavastatin at visit 0 will be prescribed at a dose of 2 mg, after 1 month in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg.~The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with pitavastatin, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). There will be visits on the 7th, 9th and 12th months.
Trial: NCT05285800
Drug: 0.5% Hyperbaric Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In both groups 0.5% Hyperbaric Bupivacaine is given intrathecally and then saddle group is advised to stay in sitting position for next 5minutes so that drug can block only lower segments of nerves, Lumber 5th to Sacral dermatomes level. The spinal group is advised to take supine position immediately so that drug distribution be uniform uptill T10 level of spinal dermatome. Then outcomes regarding haemodynamic status and vasopressor usage are recorded
Trial: NCT05325645
Drug: OPC-34712FUM/ Brexpiprazole fumarate
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 brexpiprazole QW tablets 24 mg (48 mg/dose) will be orally administered once weekly for 7weeks.(As an initial dose, one brexpiprazole QW tablet 24 mg and one placebo tablet will be orally administered (24 mg/dose))
Trial: NCT05042505
Drug: Dapagliflozin 10Mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapa group (n = 50): Patients with diabetes mellitus will receive Dapagliflozin 10 mg
Trial: NCT05042505
Drug: Sitagliptin 100mg
RxNorm normalized name: Sitagliptin 100mg Oral tablet
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sita group (n = 50): Patients with diabetes mellitus will receive sitagliptin 100 mg once daily
Trial: NCT04707625
Drug: Aflibercept Ophthalmic
RxNorm normalized name: aflibercept ophthalmic
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-vascular endothelial growth factor intraocular injection
Trial: NCT06145373
Drug: Fitusiran (SAR439774)
RxNorm normalized name: Fitusiran
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous (SC) injection
Trial: NCT05661409
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated.
Trial: NCT06558058
Drug: Rivaroxaban 10 mg film-coated tablet
RxNorm normalized name: rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One tablet of the test drug was given orally after an overnight fast.
Trial: NCT06558058
Drug: Xarelto 10 mg film-coated tablet
RxNorm normalized name: rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One tablet of the reference drug was given orally after an overnight fast.
Trial: NCT04870944
Drug: FACT Complex-targeting Curaxin CBL0137
RxNorm normalized name: Hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06157580
Drug: Compound 21
RxNorm normalized name: COMPOUND 21
DrugBank: Buloxibutid (DB18038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: differences in vasodilation to compound 21 in the skin between groups
Trial: NCT06157580
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: differences in vasoconstriction to angiotensin II in the skin between groups
Trial: NCT06011772
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03878316
Drug: Instranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal Oxytocin - concentrated formulation - 35 IU per dose
Trial: NCT06011772
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06026657
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04471246
Drug: Cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg PO QID for 7 days
Trial: NCT04471246
Drug: Cephalexin + placebo
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg PO QID plus oral placebo for 7 days
Trial: NCT05702177
Drug: Daridorexant 25 mg
RxNorm normalized name: daridorexant 25 MG
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single-dose of daridorexant 25 mg will be administered in the evening 30 minutes prior to bedtime.
Trial: NCT05702177
Drug: Daridorexant 50 mg
RxNorm normalized name: daridorexant 50 MG
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single-dose of daridorexant 50 mg will be administered in the evening 30 minutes prior to bedtime.
Trial: NCT00613574
Drug: tiotropium-bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care
Trial: NCT05781711
Drug: levodopa-carbidopa
RxNorm normalized name: carbidopa / levodopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: levodopa-carbidopa is the standard therapy used in Parkinson's disease
Trial: NCT04771000
Drug: Ambrisentan
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Endothelin receptor antagonist
Trial: NCT05781711
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin, a biguanide family member commonly used in treatment for type 2 diabetes, appears to increase liver and peripheral tissue sensitivity to insulin as well as reduce hepatic glucose production
Trial: NCT05388448
Drug: Sanfetrinem Cilexetil
RxNorm normalized name: Sanfetrinem cilexetil
DrugBank: Sanfetrinem cilexetil (DB19135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules
Trial: NCT05388448
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin will be administered at a dose of 35 mg/kg once daily for 14 days with or without sanfetrinem cilexetil.
Trial: NCT05268510
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg Pembrolizumab day 1 Q6W (max. 18 cycles)
Trial: NCT05268510
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg Olaparib bid. cont. day 1 to 42 (max. 16 cycles)
Trial: NCT05764525
Drug: VVZ-149 Injections
RxNorm normalized name: Vvz-149 free base
DrugBank: Opiranserin (DB16271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 1000 mg of VVZ-149
Trial: NCT05100654
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
Trial: NCT05100654
Drug: Augmentin
RxNorm normalized name: Augmentin
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
Trial: NCT05100654
Drug: Bactrim
RxNorm normalized name: Bactrim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
Trial: NCT06451757
Drug: Sonlicromanol
RxNorm normalized name: Sonlicromanol
DrugBank: Sonlicromanol (DB16333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 100 mg sonlicromanol (KH176) twice daily during 52 weeks
Trial: NCT05400109
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
Trial: NCT06180759
Drug: Intravenous infusion of DMT
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dose rate of 1.2 mg/min will be administered
Trial: NCT06180759
Drug: Intravenous infusion of ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dose rate of 1.0 mg/min will be administered
Trial: NCT04990830
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control Group
Trial: NCT06463834
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab: 200mg, iv, D1, Q3W;~DCF chemotherapy:~docetaxel 70mg/m2，iv，d1，Q3W； cisplatin 75mg/m2，iv，d1，Q3W； 5-fluorouracil 750-800mg/m2，iv，d1-d5，Q3W
Trial: NCT05919264
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be administered per the prescribing information in combination with FOG-001
Trial: NCT05919264
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered per the prescribing information in combination with FOG-001
Trial: NCT04340180
Drug: Standard of Care (SOC) gadolinium Breast MRI
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SOC) gadolinium Breast MRI
Trial: NCT04340180
Drug: reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
Trial: NCT06389500
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab, IV
Trial: NCT06389500
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib, PO
Trial: NCT05644769
Drug: Human sequence Ang-(1-12) on Lisinopril 40mg every day
RxNorm normalized name: lisinopril 40 MG
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Determine the presence of the human sequence of Ang-(1-12) in the plasma of 10 normal male and female hypertensive patients after four weeks on Lisinopril 40 mg every day.
Trial: NCT05555251
Drug: BI-1607
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered at different doses in Phase I by intravenous infusions every 3 weeks.
Trial: NCT05555251
Drug: BI-1607
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered at the recommended dose in Phase 2a by intravenous infusions every 3 weeks.
Trial: NCT05555251
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.
Trial: NCT05722093
Drug: Manzi Guben granules
RxNorm normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration cycle of Manzhi Guben granules: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
Trial: NCT06357858
Drug: INQOVI (decitabine and cedazuridine)
RxNorm normalized name: Inqovi
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral decitabine (ASTX727) will be administered during D1-5 (DL1) or D1-4 (DL1-1).
Trial: NCT06357858
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be administered on D8 with every 4 week cycle.
Trial: NCT06263491
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO